New Reverse Transcriptase Inhibitors in Development
msra(2006)
摘要
Since the identification of HIV as the etiological agent of AIDS, the HIV reverse transcriptase (RT) enzyme has been considered
an ideal selective antiretroviral drug (ARV) target. Although several polymerases are found in human cells, none are comparable
to HIV RT in their ability to catalyze the synthesis of new DNA from an RNA template. A selective RT inhibitor should, therefore,
exert limited toxicity. The RT enzyme plays a crucial role in the early stages of the viral life cycle and can be competitively
inhibited by chain-terminating nucleoside analogs (several of which were synthesized for basic research use well before the
discovery of HIV). Therefore, it is not surprising that nucleoside RT inhibitors (NRTIs) were the first ARVs to be made available
for the treatment of HIV infection. There now exist two additional classes of RT inhibitors, with independent modes of action;
the non-nucleoside RT inhibitors (NNRTIs), first discovered in the early 1990s (1, and the nucleotide RT inhibitors. As described in detail in the earlier chapters of this volume Chapter 11 to Chapter 14
the NNRTIs act by noncompetitive binding to a hydrophobic pocket on the p66 subunit of the RT enzyme. The consequence of NNRTI
binding to this unique site within the RT alters the ability of the enzyme to carry out its function. The current generation
of NNRTIs selectively inhibits HIV-1 replication, reflecting their very high specificity for RT. They even have no significant
activity against HIV-2, simian immunodeficiency virus, or other studied retroviruses. Unlike the NRTIs and the nucleotide
RT inhibitors, NNRTIs do not require intracellular activation through phosphorylation.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要